Portal de Periódicos da CAPES

Alive with good vision: the ultimate goal in managing retinoblastoma

2012; Wiley; Volume: 40; Issue: 7 Linguagem: Inglês

10.1111/j.1442-9071.2012.02858.x

1442-9071

Tero Kivelä,

Nonmelanoma Skin Cancer Studies

Clinical & Experimental OphthalmologyVolume 40, Issue 7 p. 655-656 Editorial Alive with good vision: the ultimate goal in managing retinoblastoma Tero Kivelä MD FEBO, Tero Kivelä MD FEBO Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, FinlandSearch for more papers by this author Tero Kivelä MD FEBO, Tero Kivelä MD FEBO Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, FinlandSearch for more papers by this author First published: 09 October 2012 https://doi.org/10.1111/j.1442-9071.2012.02858.xCitations: 5 Conflict/competing interest: None declared. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93: 1129–1131. 2 Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 2007; 114: 162–169. 3 Kim JM, Kim JH, Kim SJ et al. Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatments. Korean J Ophthalmol 2010; 24: 347–352. 4 Narang S, Mashayekhi A, Rudich D, Shields CL. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma. Clin Experiment Ophthalmol 2012; 40: 736–742. 5 Demirci H, Shields CL, Meadows AT, Shields JA. Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol 2005; 123: 1525–1530. 6 Desjardins L, Chefchaouni MC, Lumbroso L et al. Résultats fonctionnels du traitement du rétinoblastome par les traitements locaux en utilisation isolée ou associés à une chimiothérapie. J Fr Ophtalmol 2005; 28: 725–731. 7 Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol 2009; 93: 21–23. 8 Newcombe RG, Duff GR. Eyes or patients? Traps for the unwary in the statistical analysis of ophthalmological studies. Br J Ophthalmol 1987; 71: 645–646. 9 Shields CL, Kaliki S, Rojanaporn D, Al-Dahmash S, Bianciotto CG, Shields JA. Intravenous and intra-arterial chemotherapy for retinoblastoma: what have we learned? Curr Opin Ophthalmol 2012; 23: 202–209. Citing Literature Volume40, Issue7September/October 2012Pages 655-656 ReferencesRelatedInformation